Amrit Ray, B.Sc. (Hons.), M.B., Ch.B., M.B.A., serves as Chief Medical Officer and Head of the Global Medical Organization for Johnson & Johnson's pharmaceuticals group, Janssen. Dr. Ray advocates for patients across the organization and promotes ethical, evidence-based, and patient-centric decision-making. Johnson & Johnson, the world’s most comprehensive and broadly based manufacturer of health care products, has approximately 127,000 employees that work to touch the lives of over a billion people daily.
As CMO, Dr. Ray has global responsibility for ensuring the safe, effective and appropriate use of Johnson & Johnson’s 1,000+ pharmaceutical products, and for supporting an innovative research pipeline of new medicines. He Chairs the senior governance body for decision-making on safety, and Chairs the J&J bioethics committee. He leads groups responsible for the independent medical assessment of benefits and risks for all drugs, biologics and vaccines, from first human exposure through clinical trials, and all market activity. Dr. Ray is part of the R&D leadership team for Janssen’s pharmaceuticals portfolio including research programs across Oncology, Immunology, Cardiovascular, Infectious Diseases, and Neuroscience, and leads centers of special focus such as Patient Support.
By background, Dr. Ray is a physician scientist with global experience in medical research. He joined J&J in 2009 to serve as Chief Safety Officer, and was appointed CMO in 2012. Previously, he served in positions of increasing responsibility in Clinical Development, Medical Affairs, and Safety & Epidemiology at Pfizer and at Bristol-Myers Squibb. Dr. Ray earned immunology and medical degrees from Edinburgh University Medical School. Following bench research experience at Sir Joseph Lister Labs and early clinical training at Edinburgh Royal Infirmary, he began his career serving as a hospital doctor delivering patient care in the British National Health Service. He began his clinical research interests in obesity at the Mayo Clinic. Dr. Ray also earned an M.B.A. from Dartmouth’s Tuck School of Business and built business experience as a McKinsey analyst focusing on corporate finance and M&A.
Dr. Ray has been awarded distinctions for the development of new medicines in Women’s Health, Immunology and Cardiovascular, and his contributions have been recognized by the U.S. Congress, patient advocates, and public health groups. He serves on the editorial board of Therapeutic Advances in Drug Safety. Dr. Ray has authored numerous scientific papers and has provided testimony and expert input to the World Health Organization, U.S. Congress, USAID, Brookings Institution, Bill & Melinda Gates Foundation, Institute of Medicine, UK MHRA and NICE, Chinese FDA, and other international forums on how medicines can create value and have a positive impact in the lives of patients.